A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
Clinical trial NCT07757230 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07757230
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2028-02-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.